医学
痴呆
危险系数
倾向得分匹配
内科学
血管性痴呆
队列研究
队列
回顾性队列研究
糖尿病
置信区间
疾病
内分泌学
作者
Mingyang Sun,Xiaoling Wang,Zhongyuan Lu,Yi Yang,Shuang Lv,Mengrong Miao,Wan‐Ming Chen,Szu‐Yuan Wu,Jiaqiang Zhang
摘要
Abstract Aims Type 2 diabetes mellitus (T2DM) significantly increases the risk of dementia, including Alzheimer's disease (AD), vascular dementia (VaD) and mixed dementia. Although sodium‐glucose cotransporter‐2 inhibitors (SGLT2i) have shown potential neuroprotective effects, previous studies were limited by small sample sizes, single‐country datasets and a lack of detailed analyses of dementia subtypes. Materials and Methods This retrospective cohort study utilized the TriNetX database, comprising de‐identified electronic health records from over 100 million patients across 98 healthcare organizations worldwide. Adults with T2DM initiating treatment with either SGLT2i or dipeptidyl peptidase‐4 inhibitors (DPP4i) between November 20, 2004, and November 20, 2024, were included. Propensity score matching (PSM) at a 1:1 ratio ensured balanced baseline characteristics. Primary outcomes included overall dementia and specific dementia subtypes (VaD, AD, other dementias), while secondary outcomes included all‐cause mortality. Results After 1:1 propensity score matching, 278 689 patients per group were analysed. SGLT2i use was associated with a lower incidence of overall dementia (2.9% vs. 6.7%; adjusted hazard ratio [AHR] 0.77, 95% confidence interval [CI], 0.75–0.79) and a lower risk of vascular dementia (AHR 0.80), Alzheimer's disease (AHR 0.82) and other dementias (AHR 0.68). These associations remained consistent across age, sex, baseline glycaemic control and concurrent medication use in subgroup analyses. SGLT2i use was also linked to lower all‐cause mortality (4.1% vs. 11.2%; AHR 0.66, 95% CI, 0.65–0.68). Findings were robust across sensitivity and subgroup analyses, supporting the potential neuroprotective effects of SGLT2i. Conclusions This large‐scale observational study suggests that SGLT2i use is associated with lower risks of multiple dementia subtypes and all‐cause mortality in patients with T2DM.
科研通智能强力驱动
Strongly Powered by AbleSci AI